Contract News

  • 23 July 2019

    VenatoRx forms public alliance to develop new antibiotic

    VenatoRx Pharmaceuticals has partnered with the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) for a new antibiotic to treat infections...

  • 11 May 2018

    Eli Lilly buys ARMO BioSciences for $1.6bn

    Eli Lilly has announced that it will acquire immuno-oncology company ARMO BioSciences, including the company’s lead immuno-oncology product pegilodecakin, in an all-cash transaction of $50 per share, or approximately $1.6bn.


Go Top